181 related articles for article (PubMed ID: 20580994)
1. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Liu Y; Ramírez J; House L; Ratain MJ
Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Liu Y; Ramírez J; House L; Ratain MJ
Drug Metab Dispos; 2010 Jan; 38(1):32-9. PubMed ID: 19850672
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
4. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.
Fujita K; Sugiyama M; Akiyama Y; Ando Y; Sasaki Y
Cancer Chemother Pharmacol; 2011 Jan; 67(1):237-41. PubMed ID: 20814789
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.
Li W; Xing Y; Liu Y
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1253-60. PubMed ID: 25917289
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
7. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
Cai H; Nguyen N; Peterkin V; Yang YS; Hotz K; La Placa DB; Chen S; Tukey RH; Stevens JC
Drug Metab Dispos; 2010 May; 38(5):879-86. PubMed ID: 20124398
[TBL] [Abstract][Full Text] [Related]
8. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
Hanioka N; Ozawa S; Jinno H; Ando M; Saito Y; Sawada J
Xenobiotica; 2001 Oct; 31(10):687-99. PubMed ID: 11695848
[TBL] [Abstract][Full Text] [Related]
9. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
10. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Drug-Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation.
Wang Z; Wang X; Wang Z; Fan X; Yan M; Jiang L; Xia Y; Cao J; Liu Y
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):353-361. PubMed ID: 35147853
[TBL] [Abstract][Full Text] [Related]
12. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
14. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
[TBL] [Abstract][Full Text] [Related]
16. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
[TBL] [Abstract][Full Text] [Related]
17. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Yong WP; Ramirez J; Innocenti F; Ratain MJ
Clin Cancer Res; 2005 Sep; 11(18):6699-704. PubMed ID: 16166450
[TBL] [Abstract][Full Text] [Related]
18. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Wang L; Chan CEL; Wong AL; Wong FC; Lim SW; Chinnathambi A; Alharbi SA; Lee LS; Soo R; Yong WP; Lee SC; Ho PC; Sethi G; Goh BC
Oncotarget; 2017 Jun; 8(25):41572-41581. PubMed ID: 28157715
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
20. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
